Blog icon

The challenge

Influenza affects hundreds of millions of people annually

Influenza, commonly called 'the flu', affects five to 10 per cent of adults and 20 to 30 per cent of children around the world each year. The economic impact is substantial in terms of days off work and productivity lost each year.

Relenza is fighting off the flu around the globe.

In high-risk groups, complications of influenza such as pneumonia can be fatal. People at high-risk include:

  • the elderly
  • those with chronic respiratory problems
  • those with diabetes
  • those with cardiovascular disease.

In a typical Australian winter, around 3000 deaths are caused either directly by the flu, due to complications of the flu or from pneumonia.

The flu virus mutates rapidly. Humans suffer repeat infections as the immunity we develop to one infection does not protect us from subsequent mutant viruses.

Our response

Breakthrough discovery unlocks mutation pattern

In collaboration with research partners and industry, we have revolutionised the treatment of influenza with drugs of pinpoint precision.

Using x-ray crystallography, we found a region on one of the surface proteins of the flu virus that does not change in any of its strains.

We teamed up with researchers from the Victorian College of Pharmacy and the Australian National University, and designed a drug called Zanamivir that 'locks' onto this section of the virus and stops the infection progressing.

This approach is now also being used for:

  • diabetes
  • hepatitis
  • cancer.

Zanamivir was the first effective drug for treating all strains of the flu, as well as the catalyst for a new class of anti-viral agents called neuraminidase inhibitors.

Australian biotech company Biota sponsored the research and licensed the drug to GlaxoSmithKline.

The results

New drug to fight the flu globally

The drug Zanamivir is commercially available as Relenza and works against all strains of influenza virus including avian and swine flu.

It was brought to the world in 1999 and is now available in 70 countries, marketed by GlaxoSmithKline.

Clinical trials conducted by Glaxo Wellcome in Australia and overseas show that Relenza significantly reduces the duration and severity of flu symptoms, especially if it is taken soon after a person is infected.

More recently, we tested the ability of Relenza to inhibit the H5N1 influenza virus, or bird flu. Flu drugs including Relenza are considered vital for protection against future pandemics such as the H5N1 bird flu.

Neuraminidase inhibitors, such as Relenza, have worldwide annual sales in excess of $3 billion.

Do business with us to help your organisation thrive

We partner with small and large companies, government and industry in Australia and around the world.

Contact us now to start doing business

Contact us

Find out how we can help you and your business. Get in touch using the form below and our experts will get in contact soon!

CSIRO will handle your personal information in accordance with the Privacy Act 1988 (Cth) and our Privacy Policy.

First name must be filled in

Surname must be filled in

I am representing *

Please choose an option

Please provide a subject for the enquriy

0 / 100

We'll need to know what you want to contact us about so we can give you an answer

0 / 1900

You shouldn't be able to see this field. Please try again and leave the field blank.